PlainPharmaWatch

CMS Open Payments · Tool

Novocure Inc. vs bluebird bio, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

bluebird bio, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,750, versus 549 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Novocure Inc.
HHI 549 · top recipient 0.2%
Ranked #1,262 of 1,838 companies by HHI
bluebird bio, Inc.
HHI 1,750 · top recipient 0.3%
Ranked #800 of 1,838 companies by HHI

Payment Overview

Company A

Novocure Inc.

Total Payments
$4.5M
% of Industry
0.0%
Transactions
4,012
Avg per Transaction
$1.1K
Recipients
3,615
Avg per Recipient
$1.2K
Payment Types
9
Top Payment Type
Compensation for Services Other Than Consulting
Company B

bluebird bio, Inc.

Total Payments
$4.5M
% of Industry
0.0%
Transactions
377
Avg per Transaction
$11.9K
Recipients
229
Avg per Recipient
$19.6K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Novocure Inc. vs bluebird bio, Inc. - total reported payments in CMS Open Payments PY2024

bluebird bio, Inc.$4.5MNovocure Inc.$4.5M

Payment Types Breakdown

Novocure Inc.

Compensation for Services Other Than Consulting $237.5K

5.3%

Honoraria $236.3K

5.3%

Compensation for Faculty or Speaker (Medical Education) $217.6K

4.9%

Consulting Fee $193.0K

4.3%

Food and Beverage $178.4K

4.0%

Travel and Lodging $86.9K

1.9%

bluebird bio, Inc.

Consulting Fee $109.1K

2.4%

Grant $56.0K

1.2%

Compensation for Services Other Than Consulting $32.5K

0.7%

Food and Beverage $10.7K

0.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Novocure Inc.

  1. 1

    Allyson Joy Ocean

    $257,466.69 · 19 txns

  2. 2

    WADE THOMAS IAMS

    $33,450.69 · 25 txns

  3. 3

    Martin Frederik Dietrich

    $33,270.62 · 20 txns

  4. 4

    SAMUEL AARON GOLDLUST

    $31,910.90 · 35 txns

  5. 5

    JENNIFER NOEL SERVENTI

    $31,267.44 · 94 txns

bluebird bio, Inc.

  1. 1

    ANDREW DIETZ

    $69,750.00 · 9 txns

  2. 2

    JOHN O AGWUNOBI

    $32,500.00 · 2 txns

  3. 3

    University Of Virginia Medical Cente

    $29,000.00 · 2 txns

  4. 4

    Massachusetts General Hospital

    $25,000.00 · 1 txns

  5. 5

    DANIEL LOES

    $10,002.50 · 8 txns

Summary Comparison

Metric Novocure Inc. bluebird bio, Inc.
Total Payments $4.5M $4.5M
% of Industry Total 0.0% 0.0%
Transaction Count 4,012 377
Avg per Transaction $1.1K $11.9K
Recipient Count 3,615 229
Avg per Recipient $1.2K $19.6K
Payment Type Count 9 4
Top Payment Type Compensation for Services Other Than Consulting Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.